Format

Send to

Choose Destination
J Pharmacol Sci. 2019 Jun;140(2):201-204. doi: 10.1016/j.jphs.2019.05.007. Epub 2019 May 24.

Rapamycin activates mammalian microautophagy.

Author information

1
Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
2
Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Electronic address: takaseki@kumamoto-u.ac.jp.
3
Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Maebashi, Japan.
4
Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Priority Organization for Innovation and Excellence, Kumamoto University, Kumamoto, Japan; Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program", Kumamoto University, Kumamoto, Japan.

Abstract

Autophagy-lysosome proteolysis is classified into macroautophagy (MA), microautophagy (mA) and chaperone-mediated autophagy (CMA). In contrast to MA and CMA, mA have been mainly studied in yeast. In 2011, mammalian mA was identified as a pathway to deliver cytosolic proteins into multivesicular bodies. However, its molecular mechanism is quite different from yeast mA. Using a cell-based method to evaluate mA and CMA, we revealed that rapamycin, an activator of yeast mA, significantly activated mammalian mA. Although rapamycin activates MA, mA was also activated by rapamycin in MA-deficient cells. These findings suggest that rapamycin is a first-identified activator of mammalian mA.

KEYWORDS:

Chaperone-mediated autophagy; Microautophagy; Rapamycin

PMID:
31178328
DOI:
10.1016/j.jphs.2019.05.007
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center